GlycoVaxyn
Company developing a broad portfolio of bioconjugate vaccines to PREvent common bacterial infections using its proprietary glycoprotein technology
Total raised
€20M
€20,090,908
Funding rounds
2
Investors
3
distinct backers
Active since
2006-06
latest 2009-02
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood21
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 20y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2009-03-01 | Series B | €19M | Edmond de Rothschild Venture Capital,Index Ventures,Sofinnova Partners | View deal → |
| 2006-07-01 | Series A | €727k | Index Ventures,Sofinnova Partners | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy